Similar articles

• Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.

  Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E. Terashima A, et al. Int J Infect Dis. 2002 Mar;6(1):28-30. doi: 10.1016/s1201-9712(02)90132-3. Int J Infect Dis. 2002. PMID: 12044298
• Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.

  Peters L, McCarthy AE, Faught C. Peters L, et al. Int J Infect Dis. 2009 Nov;13(6):e501-3. doi: 10.1016/j.ijid.2009.02.009. Epub 2009 Jun 4. Int J Infect Dis. 2009. PMID: 19501008
• Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.

  Ashida C, Kinoshita K, Nozaki Y, Funauchi M. Ashida C, et al. BMC Infect Dis. 2020 Jul 2;20(1):470. doi: 10.1186/s12879-020-05195-0. BMC Infect Dis. 2020. PMID: 32615937 Free PMC article.
• Reactive arthritis induced by Strongyloides stercoralis.

  Brocq O, Breuil V, Agopian V, Grisot C, Flory P, Bernard-Pomier G, Ziegler G, Euller-Ziegler L. Brocq O, et al. Rev Rhum Engl Ed. 1996 Mar;63(3):217-9. Rev Rhum Engl Ed. 1996. PMID: 8731241 Review.
• Treatment strategies in controlling strongyloidiasis.

  Satoh M, Kokaze A. Satoh M, et al. Expert Opin Pharmacother. 2004 Nov;5(11):2293-301. doi: 10.1517/14656566.5.11.2293. Expert Opin Pharmacother. 2004. PMID: 15500376 Review.